-
1
-
-
16444366265
-
Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: An interim analysis
-
Adler LA, Spencer TJ, Milton DR, et al. 2005. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. J Clin Psychiatry, 66:294-9.
-
(2005)
J Clin Psychiatry
, vol.66
, pp. 294-299
-
-
Adler, L.A.1
Spencer, T.J.2
Milton, D.R.3
-
2
-
-
33645739829
-
Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders
-
Allen AJ, Kurlan RM, Gilbert DL, et al. 2005. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology, 65:1941-9.
-
(2005)
Neurology
, vol.65
, pp. 1941-1949
-
-
Allen, A.J.1
Kurlan, R.M.2
Gilbert, D.L.3
-
3
-
-
6344263841
-
Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder
-
Aman M. 2004. Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder. Semin Pediatr Neurol, 11:225-8.
-
(2004)
Semin Pediatr Neurol
, vol.11
, pp. 225-228
-
-
Aman, M.1
-
4
-
-
0004235298
-
-
[APA] American, Psychiatric Association. 4th ed, text revision (DSM-IV-TR). Washington DC: APA
-
[APA] American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text revision (DSM-IV-TR). Washington DC: APA.
-
(2000)
Diagnostic and Statistical Manual of Mental Disorders
-
-
-
5
-
-
0029924275
-
The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder
-
Arnsten AF, Steere JC, Hunt RD. 1996. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry, 53:448-55.
-
(1996)
Arch Gen Psychiatry
, vol.53
, pp. 448-455
-
-
Arnsten, A.F.1
Steere, J.C.2
Hunt, R.D.3
-
7
-
-
0036838952
-
Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics
-
Belle DJ, Ernest CS, Sauer JM, et al. 2002. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol, 42:1219-27.
-
(2002)
J Clin Pharmacol
, vol.42
, pp. 1219-1227
-
-
Belle, D.J.1
Ernest, C.S.2
Sauer, J.M.3
-
8
-
-
0036884937
-
Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder
-
[online]
-
Biederman J, Heiligenstein JH, Faries DE, et al. 2002. Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/ hyperactivity disorder [online]. Pediatrics, 110:e75. URL: http://pediatrics.aappublications.org/.
-
(2002)
Pediatrics
, vol.110
-
-
Biederman, J.1
Heiligenstein, J.H.2
Faries, D.E.3
-
9
-
-
1942507310
-
Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: Four case reports
-
Brown TE. 2004. Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: four case reports. J Child Adolesc Psychopharmacol, 14:129-36.
-
(2004)
J Child Adolesc Psychopharmacol
, vol.14
, pp. 129-136
-
-
Brown, T.E.1
-
10
-
-
3142706616
-
A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD
-
Buitelaar JK, Danckaerts M, Gillberg C, et al. 2004. A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. Eur Child Adolesc Psychiatry, 13:249-57.
-
(2004)
Eur Child Adolesc Psychiatry
, vol.13
, pp. 249-257
-
-
Buitelaar, J.K.1
Danckaerts, M.2
Gillberg, C.3
-
11
-
-
0036848458
-
Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder
-
Bymaster FP, Karner JS, Nelson DL, et al. 2002. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/ hyperactivity disorder. Neuropsychopharmacology, 27:699-711.
-
(2002)
Neuropsychopharmacology
, vol.27
, pp. 699-711
-
-
Bymaster, F.P.1
Karner, J.S.2
Nelson, D.L.3
-
12
-
-
0037374404
-
Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites
-
Chalon SA, Desager JP, Desante KA, et al. 2003. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Clin Pharmacol Ther, 73:178-91.
-
(2003)
Clin Pharmacol Ther
, vol.73
, pp. 178-191
-
-
Chalon, S.A.1
Desager, J.P.2
Desante, K.A.3
-
13
-
-
31544459553
-
The use of antidepressants to treat depression in children and adolescents
-
Cheung AH, Emslie GJ, Mayes TL. 2006. The use of antidepressants to treat depression in children and adolescents. CMAJ, 174:193-200.
-
(2006)
CMAJ
, vol.174
, pp. 193-200
-
-
Cheung, A.H.1
Emslie, G.J.2
Mayes, T.L.3
-
14
-
-
29544449443
-
Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19
-
deLeon J, Armstrong SC, Cozza KL. 2006. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics, 47:75-85.
-
(2006)
Psychosomatics
, vol.47
, pp. 75-85
-
-
deLeon, J.1
Armstrong, S.C.2
Cozza, K.L.3
-
15
-
-
33847267772
-
Use of plasma concentration to guide atomoxetine doses in ADHD patients
-
2005 May; Atlanta, GA, USA
-
Dunn DW, Turgay A, Weiss M, et al. 2005. Use of plasma concentration to guide atomoxetine doses in ADHD patients. American Psychiatry Association Annual Meeting. 2005 May; Atlanta, GA, USA. p 187.
-
(2005)
American Psychiatry Association Annual Meeting
, pp. 187
-
-
Dunn, D.W.1
Turgay, A.2
Weiss, M.3
-
16
-
-
33847279418
-
Package Insert, Strattera™
-
Eli Lilly and Company
-
Eli Lilly and Company. 2003. Package Insert, Strattera™.
-
(2003)
-
-
-
17
-
-
33745567446
-
Atomoxetine for weight reduction in obese women: A preliminary randomized controlled trial
-
[online]. Accessed April 15 2006
-
Gadde KM, Yonish GM, Wagner HR, et al. 2006. Atomoxetine for weight reduction in obese women: a preliminary randomized controlled trial [online]. Int J Obes. Accessed April 15 2006. URL: http://www.nature.com/ ijo/journal/vaop/ncurrent/abs/0803223a.html.
-
(2006)
Int J Obes.
-
-
Gadde, K.M.1
Yonish, G.M.2
Wagner, H.R.3
-
18
-
-
30944446392
-
Comparison of the inhibitory and excitatory effects of ADHD medications methylphenidate and atomoxetine on motor cortex
-
Gilbert DL, Ridel KR, Sallee FR, et al. 2006. Comparison of the inhibitory and excitatory effects of ADHD medications methylphenidate and atomoxetine on motor cortex. Neuropsychopharmacology, 31:442-9.
-
(2006)
Neuropsychopharmacology
, vol.31
, pp. 442-449
-
-
Gilbert, D.L.1
Ridel, K.R.2
Sallee, F.R.3
-
19
-
-
29944443819
-
Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents with bipolar disorders
-
Hah M, Chang K. 2005. Atomoxetine for the treatment of attention-deficit/ hyperactivity disorder in children and adolescents with bipolar disorders. J Child Adolesc Psychopharmacol, 15:996-1004.
-
(2005)
J Child Adolesc Psychopharmacol
, vol.15
, pp. 996-1004
-
-
Hah, M.1
Chang, K.2
-
20
-
-
0036644683
-
Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users
-
Heil SH, Holmes HW, Bickel WK, et al. 2002. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend, 67:149-56.
-
(2002)
Drug Alcohol Depend
, vol.67
, pp. 149-156
-
-
Heil, S.H.1
Holmes, H.W.2
Bickel, W.K.3
-
21
-
-
4644281608
-
Mania induction associated with atomoxetine
-
Henderson TA. 2004. Mania induction associated with atomoxetine. J Clin Psychopharmacol, 24:567-8.
-
(2004)
J Clin Psychopharmacol
, vol.24
, pp. 567-568
-
-
Henderson, T.A.1
-
22
-
-
12344311419
-
Aggression, mania, and hypomania induction associated with atomoxetine
-
Henderson TA, Hartman K. 2004. Aggression, mania, and hypomania induction associated with atomoxetine. Pediatrics, 114:895-6.
-
(2004)
Pediatrics
, vol.114
, pp. 895-896
-
-
Henderson, T.A.1
Hartman, K.2
-
23
-
-
11444255970
-
Efficacy and safety of atomoxetine in childhood attention-deficit /hyperactivity disorder with comorbid oppositional defiant disorder
-
Kaplan S, Heiligenstein J, West S, et al. 2004. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord, 8:45-52.
-
(2004)
J Atten Disord
, vol.8
, pp. 45-52
-
-
Kaplan, S.1
Heiligenstein, J.2
West, S.3
-
24
-
-
0028933970
-
Pharmacogenetics and Development: Are infants and children at increased risk for adverse outcomes?
-
Kearns, GL. 1995. Pharmacogenetics and Development: Are infants and children at increased risk for adverse outcomes? Curr Opinion Pediatr, 7:220-233.
-
(1995)
Curr Opinion Pediatr
, vol.7
, pp. 220-233
-
-
Kearns, G.L.1
-
25
-
-
4644226347
-
Once-daily atomoxetine treatment for children with attention-deficit /hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial
-
[online]
-
Kelsey DK, Sumner CR, Casat CD, et al. 2004. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial [online]. Pediatrics, 114:e1-8. URL: http://pediatrics.aappublications.org/.
-
(2004)
Pediatrics
, vol.114
-
-
Kelsey, D.K.1
Sumner, C.R.2
Casat, C.D.3
-
26
-
-
28444486103
-
Morning-versus evening-dosed atomoxetine: Effects of core ADHD symptoms
-
May; Atlanta, GA, USA
-
Kelsey DK, Sutton V, Lewis D, et al. Morning-versus evening-dosed atomoxetine: effects of core ADHD symptoms, American Psychiatry Association Annual Meeting. 2005 May; Atlanta, GA, USA. p 173.
-
(2005)
American Psychiatry Association Annual Meeting
, pp. 173
-
-
Kelsey, D.K.1
Sutton, V.2
Lewis, D.3
-
27
-
-
0034960305
-
An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder
-
Kratochvil CJ, Bohac D, Harrington M, et al. 2001. An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol, 11:167-70.
-
(2001)
J Child Adolesc Psychopharmacol
, vol.11
, pp. 167-170
-
-
Kratochvil, C.J.1
Bohac, D.2
Harrington, M.3
-
28
-
-
0036633805
-
Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial
-
Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. 2002. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry, 41:776-84.
-
(2002)
J Am Acad Child Adolesc Psychiatry
, vol.41
, pp. 776-784
-
-
Kratochvil, C.J.1
Heiligenstein, J.H.2
Dittmann, R.3
-
29
-
-
23944461087
-
Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms
-
Kratochvil CJ, Newcorn JH, Arnold LE, et al. 2005. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry, 44:915-24.
-
(2005)
J Am Acad Child Adolesc Psychiatry
, vol.44
, pp. 915-924
-
-
Kratochvil, C.J.1
Newcorn, J.H.2
Arnold, L.E.3
-
30
-
-
19544392513
-
Atomoxetine use associated with onset of a motor tic
-
Ledbetter M. 2005. Atomoxetine use associated with onset of a motor tic. J Child Adolesc Psychopharmacol, 15:331-3.
-
(2005)
J Child Adolesc Psychopharmacol
, vol.15
, pp. 331-333
-
-
Ledbetter, M.1
-
32
-
-
12244298956
-
Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies
-
Michelson D, Adler L, Spencer T, et al. 2003. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry, 53:112-20.
-
(2003)
Biol Psychiatry
, vol.53
, pp. 112-120
-
-
Michelson, D.1
Adler, L.2
Spencer, T.3
-
33
-
-
0036842531
-
Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study
-
Michelson D, Allen AJ, Busner J, et al. 2002. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry, 159:1896-901.
-
(2002)
Am J Psychiatry
, vol.159
, pp. 1896-1901
-
-
Michelson, D.1
Allen, A.J.2
Busner, J.3
-
34
-
-
3042559692
-
Relapse prevention in pediatric patients with ADHD treated with atomoxetine: A randomized, double-blind, placebo-controlled study
-
Michelson D, Buitelaar JK, Danckaerts M, et al. 2004. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry, 43:896-904.
-
(2004)
J Am Acad Child Adolesc Psychiatry
, vol.43
, pp. 896-904
-
-
Michelson, D.1
Buitelaar, J.K.2
Danckaerts, M.3
-
35
-
-
0035511622
-
Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study
-
[online]
-
Michelson D, Faries D, Wernicke J, et al. 2001. Atomoxetine in the treatment of children and adolescents with attention-deficit/ hyperactivity disorder: a randomized, placebo-controlled, dose-response study [online]. Pediatrics, 108:e83. URL: http://pediatrics.aappublications.org/.
-
(2001)
Pediatrics
, vol.108
-
-
Michelson, D.1
Faries, D.2
Wernicke, J.3
-
36
-
-
14544286013
-
Atomoxetine treatment in children and adolescents with attention-deficit /hyperactivity disorder and comorbid oppositional defiant disorder
-
Newcorn JH, Spencer TJ, Biederman J, et al. 2005. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry, 44:240-8.
-
(2005)
J Am Acad Child Adolesc Psychiatry
, vol.44
, pp. 240-248
-
-
Newcorn, J.H.1
Spencer, T.J.2
Biederman, J.3
-
38
-
-
13244277705
-
A new paradigm for developing drugs in children: Atomoxetine as a model
-
Prasad S. 2005. A new paradigm for developing drugs in children: atomoxetine as a model. Arch Dis Child, 90(Suppl 1):13-16.
-
(2005)
Arch Dis Child
, vol.90
, Issue.SUPPL. 1
-
-
Prasad, S.1
-
40
-
-
13844276613
-
Attention-deficit/hyperactivity disorder: Cognitive evoked potential (P300) amplitude predicts treatment response to atomoxetine
-
Epub 2004 Nov 19
-
Sangal RB, Sangal JM. 2005. Attention-deficit/hyperactivity disorder: cognitive evoked potential (P300) amplitude predicts treatment response to atomoxetine. Clin Neurophysiol, 116:640-7. Epub 2004 Nov 19. URL: http://www.elsevier.com.
-
(2005)
Clin Neurophysiol
, vol.116
, pp. 640-647
-
-
Sangal, R.B.1
Sangal, J.M.2
-
41
-
-
33847260253
-
The American Academy of Child and Adolescent Psychiatry (AACAP) Response to FDA's Public Health Advisory on Atomoxetine
-
[online]. Accessed 18 April 2006
-
Sarles R. 2005. The American Academy of Child and Adolescent Psychiatry (AACAP) Response to FDA's Public Health Advisory on Atomoxetine [online]. Accessed 18 April 2006. URL: http://www.aacap.org/ press_releases/index.htm.
-
(2005)
-
-
Sarles, R.1
-
43
-
-
1842532596
-
Seizures and prolonged QTc with atomoxetine overdose
-
Sawant S, Daviss SR. 2004. Seizures and prolonged QTc with atomoxetine overdose. Am J Psychiatry, 161:757.
-
(2004)
Am J Psychiatry
, vol.161
, pp. 757
-
-
Sawant, S.1
Daviss, S.R.2
-
44
-
-
10944237953
-
Attention deficit disorder and epilepsy
-
Schubert R. 2005. Attention deficit disorder and epilepsy. Pediatr Neurol, 32:1-10.
-
(2005)
Pediatr Neurol
, vol.32
, pp. 1-10
-
-
Schubert, R.1
-
45
-
-
0034786182
-
An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder
-
Spencer T, Biederman J, Heiligenstein J. 2001. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol, 11:251-65.
-
(2001)
J Child Adolesc Psychopharmacol
, vol.11
, pp. 251-265
-
-
Spencer, T.1
Biederman, J.2
Heiligenstein, J.3
-
46
-
-
0031977617
-
Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder
-
Spencer T, Biederman J, Wilens T, et al. 1998. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry, 155:693-5.
-
(1998)
Am J Psychiatry
, vol.155
, pp. 693-695
-
-
Spencer, T.1
Biederman, J.2
Wilens, T.3
-
47
-
-
0036928919
-
Overview and neurobiology of attention-deficit/hyperactivity disorder
-
Spencer TJ, Biederman J, Wilens TE, et al. 2002. Overview and neurobiology of attention-deficit/hyperactivity disorder. J Clin Psychiatry, 63(Suppl 12):3-9.
-
(2002)
J Clin Psychiatry
, vol.63
, Issue.SUPPL. 12
, pp. 3-9
-
-
Spencer, T.J.1
Biederman, J.2
Wilens, T.E.3
-
48
-
-
0036935774
-
Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder
-
Spencer T, Heiligenstein JH, Biederman J, et al. 2002. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry, 63:1140-7.
-
(2002)
J Clin Psychiatry
, vol.63
, pp. 1140-1147
-
-
Spencer, T.1
Heiligenstein, J.H.2
Biederman, J.3
-
49
-
-
18844395143
-
Atomoxetine ingestions in children: A report from poison centers
-
Spiller HA, Lintner CP, Winter ML. 2005. Atomoxetine ingestions in children: a report from poison centers. Ann Pharmacother, 39:1045-8.
-
(2005)
Ann Pharmacother
, vol.39
, pp. 1045-1048
-
-
Spiller, H.A.1
Lintner, C.P.2
Winter, M.L.3
-
50
-
-
0004010456
-
-
28th ed. Hagerstown, MD: Lippincott, Williams & Wilkins
-
Stedman's Medical Dictionary. 2005. 28th ed. Hagerstown, MD: Lippincott, Williams & Wilkins.
-
(2005)
Stedman's Medical Dictionary
-
-
-
51
-
-
13744257053
-
Managing attention deficit/hyperactivity disorder: Unmet needs and future directions
-
Steer CR. 2005. Managing attention deficit/hyperactivity disorder: unmet needs and future directions. Arch Dis Child, 90(Suppl 1):i19-25.
-
(2005)
Arch Dis Child
, vol.90
, Issue.SUPPL. 1
-
-
Steer, C.R.1
-
52
-
-
0022289783
-
A case of mania associated with tomoxetine
-
Steinberg S, Chouinard G. 1985. A case of mania associated with tomoxetine. Am J Psychiatry, 142:1517-8.
-
(1985)
Am J Psychiatry
, vol.142
, pp. 1517-1518
-
-
Steinberg, S.1
Chouinard, G.2
-
54
-
-
4444267262
-
Atomoxetine and nonresponders to stimulants
-
Velcea G, Winsberg BG. 2004. Atomoxetine and nonresponders to stimulants. Am J Psychiatry, 161:1718-9.
-
(2004)
Am J Psychiatry
, vol.161
, pp. 1718-1719
-
-
Velcea, G.1
Winsberg, B.G.2
-
55
-
-
21044444747
-
A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD
-
Weiss M, Tannock R, Kratochvil C, et al. 2005. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry, 44:647-55.
-
(2005)
J Am Acad Child Adolesc Psychiatry
, vol.44
, pp. 647-655
-
-
Weiss, M.1
Tannock, R.2
Kratochvil, C.3
-
56
-
-
0033429268
-
Decreased capacity for debrisoquine metabolism among black Tanzanians: Analyses of the CYP2D6 genotype and phenotype
-
Wennerholm A, Johansson I, Massele AY, et al. 1999. Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics, 9:707-14.
-
(1999)
Pharmacogenetics
, vol.9
, pp. 707-714
-
-
Wennerholm, A.1
Johansson, I.2
Massele, A.Y.3
-
57
-
-
9144256611
-
Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: A prospective, placebo-controlled assessment
-
Wernicke JF, Adler L, Spencer T, et al. 2004. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol, 24:30-5.
-
(2004)
J Clin Psychopharmacol
, vol.24
, pp. 30-35
-
-
Wernicke, J.F.1
Adler, L.2
Spencer, T.3
-
58
-
-
0043124593
-
Cardiovascular effects of atomoxetine in children, adolescents, and adults
-
Wernicke JF, Faries D, Girod D, et al. 2003. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf, 26:729-40.
-
(2003)
Drug Saf
, vol.26
, pp. 729-740
-
-
Wernicke, J.F.1
Faries, D.2
Girod, D.3
-
59
-
-
31444442249
-
Do children and adolescents with ADHD respond differently to atomoxetine?
-
Wilens, TE, Kratochvil C, Newcorn JH, et al. 2006. Do children and adolescents with ADHD respond differently to atomoxetine? J Am Acad Child Adolesc Psychiatry, 45:149-57.
-
(2006)
J Am Acad Child Adolesc Psychiatry
, vol.45
, pp. 149-157
-
-
Wilens, T.E.1
Kratochvil, C.2
Newcorn, J.H.3
-
61
-
-
0038556715
-
Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder
-
Witcher JW, Long A, Smith B, et al. 2003. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol, 13:53-63.
-
(2003)
J Child Adolesc Psychopharmacol
, vol.13
, pp. 53-63
-
-
Witcher, J.W.1
Long, A.2
Smith, B.3
-
62
-
-
0021926971
-
Clinical pharmacology of tomoxetine, a potential antidepressant
-
Zerbe RL, Rowe H, Enas CG, et al. 1985. Clinical pharmacology of tomoxetine, a potential antidepressant. J Pharmacol Exp Ther, 232:139-43.
-
(1985)
J Pharmacol Exp Ther
, vol.232
, pp. 139-143
-
-
Zerbe, R.L.1
Rowe, H.2
Enas, C.G.3
|